NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Health Canada has authorized Moderna's updated COVID-19 vaccine to roll out in fall immunization campaigns. The new Spikevax ...

Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity ...

The KP.3 variant of SARS-CoV-2 is dominating in Canada right now, accounting for the majority of the COVID-19 cases in the ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Analysts expressed skepticism about plans detailed by Moderna’s R&D chief Stephen Hoge to trim research spending in ...

Moderna said it planned an approximately 20% reduction in expected research and development expenses for 2025 to 2028 from $20 billion to $16 billion. It expects a reduction of about $1.1 billion in ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...

Expects to submit next-generation COVID vaccine for approval in 2024 Expects to submit flu/COVID combination vaccine for approval in 2024 Announces positive Phase 3 results for its RSV vaccine for ...

Shares of Moderna have plunged 26.1% so far this year compared with the industry’s decline of 0.9%. Image Source: Zacks Investment Research Spikevax, targeting the variant JN.1., is currently ...

The endorsement comes as Moderna's updated Spikevax COVID-19 vaccine formulation, targeting the JN.1 variant, received approval from the Taiwan Food & Drug Administration. This follows recent ...